Company Analysis
Sign in

Editas Medicine, Inc. (EDIT)

Nasdaq: EDIT · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2015
Full chart Alerts Compare
Grade4.8
◀ Past 5.2● Present 4.1▶ Future 5.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

50 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Editas Medicine, Inc.’s names, not what it holds today.

Patents granted
50
50 utility, 1976 to Dec 31, 2025
Granted in 2025
10
Against 7 in 2024 and 8 in 2023
Applications published
125
8 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology37
Pharmaceuticals3
Computer technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
EDITAS MEDICINE, INC. its own name
US, as the owner printed on each patent. 12 more under the same name are not counted (printed in GB)
50 granted
50 published
EDITAS MEDICINE, INC. its own name
named as the applicant on its applications, in US
0 granted
75 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,460,231Crispr/CAS-related methods and compositions for treating primary open angle glaucomaBiotechnologyEDITAS MEDICINE, INC.
Jul 15, 202512,359,223Systems and methods for modulating chromosomal rearrangementsBiotechnologyEDITAS MEDICINE, INC.
Jun 24, 202512,338,436Synthetic guide molecules, compositions and methods relating theretoBiotechnologyEDITAS MEDICINE, INC.
Jun 17, 202512,331,328CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndromeBiotechnologyEDITAS MEDICINE, INC.
Jun 10, 202512,325,854Crispr-CPF1-related methods, compositions and components for cancer immunotherapyBiotechnologyEDITAS MEDICINE, INC.
May 13, 202512,297,466Engineered Cas9 nucleasesBiotechnologyEDITAS MEDICINE, INC.
Apr 29, 202512,286,727Assessing nuclease cleavageBiotechnologyEDITAS MEDICINE, INC.
Apr 1, 202512,264,331Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNABiotechnologyEDITAS MEDICINE, INC.
Feb 25, 202512,234,449CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10)BiotechnologyEDITAS MEDICINE, INC.
Jan 21, 202512,201,699Compositions and methods for promoting homology directed repairBiotechnologyEDITAS MEDICINE, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 13, 20252025/0346875CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher SyndromeBiotechnologyEDITAS MEDICINE, INC.
Oct 16, 20252025/0320491CRISPR-CPF1-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPYBiotechnologyEDITAS MEDICINE, INC.
Oct 2, 20252025/0305003GENOME EDITING OF CELLSBiotechnologyEDITAS MEDICINE, INC.
Sep 25, 20252025/0297288GENOME EDITING OF B CELLSBiotechnologyEDITAS MEDICINE, INC.
Sep 18, 20252025/0288698COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIRBiotechnologyEDITAS MEDICINE, INC.
Aug 7, 20252025/0250588SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESBiotechnologyEDITAS MEDICINE, INC.
Jun 5, 20252025/0179488SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESBiotechnologyEDITAS MEDICINE, INC.
Jan 23, 20252025/0025572ENGINEERED CRISPR/CAS12A EFFECTOR PROTEINS, AND USES THEREOFBiotechnologyEDITAS MEDICINE, INC.
Dec 19, 20242024/0417706SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESBiotechnologyEDITAS MEDICINE, INC.
Nov 7, 20242024/0366680TREATMENT OF PAINBiotechnologyEDITAS MEDICINE, INC.
What it applied for, 2024 to 2025: Biotechnology 23 · Organic fine chemistry 1 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton EDIT · research, not advice